ArticleBiomolecules2024
Evaluation of Plasma E-Selectin Concentration as a Risk Marker for Atherosclerotic Vascular Damage in Patients with Early CAD.
Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vasculoprotective role of del Nido cardioplegia in open-heart surgery via modulation of E-Selectin, Endocan, and TNF-alpha coronary sinus blood samples.Journal of cardiothoracic surgery · 2025Article
- Is TGF-β Associated with Cytokines and Other Biochemical or Clinical Risk Parameters in Early-Onset CAD Patients?Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation markers in the blood may indicate a higher risk of unstable atherosclerosis. Selectins, a group of transmembrane glycoproteins, contribute to inflammation by helping certain blood cells bind to the endothelium.
methodsThe study included 100 patients with stable early-onset coronary artery disease (CAD), 75 men (aged 50-54) and 25 women (aged 55-64). Tests performed included biochemical analysis, ultrasound, and Doppler imaging of arteries and peripheral vessels. A biochemical control group of 50 cases without CAD (74% men, average age 48 ± 3.20 years) was also studied.
resultsHigher triglyceride levels were strongly linked to elevated plasma E-selectin levels. However, no significant relationship was found between plasma E-selectin levels and biochemical, clinical, radiographic, or echographic measures.
conclusionPlasma E-selectin levels are not a reliable marker for detecting atherosclerotic plaques or related problems in individuals with stable, well-managed CAD. While E-selectin levels can be measured in clinical labs using immunoassays, they cannot replace standard cardiological and vascular imaging tests for diagnosing cardiac or vascular conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.